NeoGenomics [NEO] Unchanged to Outperform at SVB Leerink
SVB Leerink maintained its NeoGenomics [NEO] rating to the equivalent of Outperform but changed the price target to $60.0 from $50, in a research note dated 2021-01-08. That figure represents around a 12.11% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with Needham’s analysts reiterating the shares to […]
Newstead Jennifer Has Sold $83,204 in Facebook Inc. [FB] Stock
On Jan. 05, Newstead Jennifer divested U.S. $83,204 in shares of Facebook Inc.. The VP, GC sold 310 shares at a price per share of $268.40. The transaction decreased this specific insider’s holdings to 1,572 shares worth around $0.42 million at present. Meanwhile, Monness Crespi & Hardt had maintained its rating on FB to the […]
TRI Pointe Group [TPH] gets a downgrade to Sector Perform from RBC Capital
RBC Capital took its TRI Pointe Group [TPH] rating to the equivalent of Sector Perform from Outperform, and the price target to $19.0 from $22, in a research note dated 2021-01-08. That figure represents around a 0.16% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with Wedbush’s analysts […]
SVB Leerink reiterates Sarepta Therapeutics [SRPT] rating to Outperform and sets new price target at $125
SVB Leerink maintained its Sarepta Therapeutics [SRPT] rating to the equivalent of Outperform but changed the price target to $125.0 from $197, in a research note dated 2021-01-08. That figure represents around a -26.01% premium from where the company’s shares closed on Thursday. Some new analysts also started their coverage, with UBS’s analysts assigning the […]
SI-BONE Inc. [SIBN] Insider Just Sold 40,000 Shares. Should You?
On Jan. 05, Dunn Jeffrey W divested U.S. $1,153,776 in shares of SI-BONE Inc.. The COB, Pres, CEO sold 40,000 shares at a price per share of $28.84. The transaction decreased this specific insider’s holdings to 459,818 shares worth around $13.33 million at present. Needham maintained its SI-BONE Inc. [SIBN] rating to the equivalent of […]
RPM International [RPM] Stock Gets a Downgrade from RBC Capital. It’s Now Sector Perform
RBC Capital took its RPM International [RPM] rating to the equivalent of Sector Perform from Outperform, and the price target to $98.0 from $102, in a research note dated 2021-01-08. That figure represents around a 11.33% premium from where the company’s shares closed on Thursday. Some new analysts also started their coverage, with Evercore ISI’s […]
Cabaletta Bio [CABA] Initiated At Buy by Chardan Capital
Chardan Capital launched its Cabaletta Bio [CABA] rating to the equivalent of Buy and assigned the price target of $21.0, in a research note dated 2021-01-08. That figure represents around a 60.67% premium from where the company’s shares closed on Thursday. Some new analysts also started their coverage, with Morgan Stanley’s analysts assigning the shares […]
DocuSign Inc. [DOCU] Sees 5,800 Share Insider Sell From COO Olrich Scott V.
On Jan. 06, Olrich Scott V. divested U.S. $1,304,252 in shares of DocuSign Inc.. The COO sold 5,800 shares at a price per share of $224.87. The transaction decreased this specific insider’s holdings to 208,746 shares worth around $49.9 million at present. Piper Sandler took its DocuSign Inc. [DOCU] rating to the equivalent of an […]
SVB Leerink lowers Myovant Sciences [MYOV] rating to Market Perform and sets price target at $28
SVB Leerink took its Myovant Sciences [MYOV] rating to the equivalent of Market Perform from Outperform, and the price target to $28.0 from $30, in a research note dated 2021-01-08. That figure represents around a 11.02% premium from where the company’s shares closed on Thursday. Meanwhile, Goldman had launched its coverage on MYOV with “Buy”, […]
DA Davidson reiterates Helen Of Troy at Buy and assigns price target at $260
DA Davidson maintained its Helen Of Troy [HELE] rating to the equivalent of Buy but changed the price target to $260.0 from $248, in a research note dated 2021-01-08. That figure represents around a 16.33% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with BofA/Merrill’s analysts reiterating the […]
